Table 8.
Ongoing clinical trials optimizing prophylactic anticoagulation regimens in COVID-19
| NCT number | Study name | Interventions | Sponsor |
|---|---|---|---|
| NCT04409834 | Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial | Evaluation of varying anticoagulation strategies including UFH IV, UFH SC, enoxaparin 1 mg/kg, enoxaparin 40 mg SC, and clopidogrel | The TIMI Study Group |
| NCT04367831 | Intermediate or Prophylactic- Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 | Evaluation of prophylactic enoxaparin vs intermediate dosing | Columbia University (USA) |
| NCT04367831 | Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients with Different Anticoagulant Regimes | Completed dose finding study of tinzaparin | Karolinska Institute (Sweden) |
| NCT04367831 | Preventing COVID-19 Complications with Low- and High-dose Anticoagulation | Evaluating low vs high dose enoxaparin | University Hospital Geneva (Switzerland) |
| NCT04344756 | Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort | Evaluation of tinzaparin vs UFH anticoagulation | Assistance Publique – Hȏpitaux de Paris (France) |
| NCT04360824 | Covid-19 Associated Coagulopathy | Evaluation of prophylactic vs intermediate dose thromboprophylaxis | University of Iowa (USA) |
| NCT04360824 | Full Dose Heparin Vs. Prophylactic or Intermediate Dose Heparin in High Risk COVID-19 Patients | Evaluation of prophylactic vs intermediate dose thromboprophylaxis | Northwell Health (USA) |
| NCT04372589 | Full Dose Heparin Vs. Prophylactic or Intermediate Dose Heparin in High Risk COVID-19 Patients | Evaluation of heparin dose strategy | University of Manitoba (Canada) |
Abbreviations: COVID-19 coronavirus disease 2019, SC subcutaneous, UFH unfractionated heparin